Shanghai, China, April 1, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical company specializing in discovering, developing, and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, will unveiled the drug and equipment performance results from the Phase III clinical study of its bladder cancer diagnostic and management drug APL-1706 in combination with HD 4K blue light cystoscopy at the 39th Annual Meeting of the European Association of Urology (EAU) on April 5-8, 2024, in Paris. in the form of an oral presentation.
Abstract ID：A1032
Date： April 8, 2024
Abstract Title: A prospective, comparative, within-patient controlled multicenter phase III study comparing blue light cystoscopy in combination with APL-1706 versus white light cystoscopy for the detection of bladder cancer using modern HD 4K equipment
Professor Hu Hailong from Tianjin Medical University Second Hospital will be the speaker.
The new drug application (NDA) for APL-1706 was accepted by the National Medical Products Administration (NMPA) in November 2023.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
